LIVIVO - Search results -

Search results

Result 1 - 10 of total 10

Search options

Article: Development of TLR9 agonists for cancer therapy.

Krieg, Arthur M

2007 Volume 117, Issue 5, Page(s) 1184–1194

Abstract: ... of cancer. TLR9 detects the unmethylated CpG dinucleotides prevalent in bacterial and viral DNA but not ... to cancer vaccines and in combination with conventional chemotherapy and other therapies. ... immune responses when they detect highly conserved pathogen-expressed molecules. Synthetic agonists ...

Abstract	In vertebrates, the TLRs are a family of specialized immune receptors that induce protective immune responses when they detect highly conserved pathogen-expressed molecules. Synthetic agonists for several TLRs, including TLR3, TLR4, TLR7, TLR8, and TLR9, have been or are being developed for the treatment of cancer. TLR9 detects the unmethylated CpG dinucleotides prevalent in bacterial and viral DNA but not in vertebrate genomes. As discussed in this Review, short synthetic oligodeoxynucleotides containing these immune stimulatory CpG motifs activate TLR9 in vitro and in vivo, inducing innate and adaptive immunity, and are currently being tested in multiple phase II and phase III human clinical trials as adjuvants to cancer vaccines and in combination with conventional chemotherapy and other therapies.
MeSH term(s)	Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/pharmacology ; Drug Design ; Humans ; Neoplasms/drug therapy ; Neoplasms/immunology ; Neoplasms/metabolism ; Toll-Like Receptor 9/agonists
Chemical Substances	Antineoplastic Agents ; Toll-Like Receptor 9
Language	English
Publishing date	2007-05-02
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	3067-3
ISSN	1558-8238 ; 0021-9738
ISSN (online)	1558-8238
ISSN	0021-9738
DOI	10.1172/JCI31414
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.184: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy.

Jin, Yizhen / Zhuang, Yuxin / Dong, Xiaowu / Liu, Mei

Expert review of anticancer therapy

2021 Volume 21, Issue 8, Page(s) 841–851

Abstract: ... limitations and prospects of TLR9 agonists in cancer immunotherapy are also discussed.: Expert opinion ... To date, CpG oligodeoxynucleotide (ODN)-based TLR9 agonists have undergone four generations ... of TLR9 agonists and summarized the optimization strategies of each generation. The applications ...

Abstract	Introduction: Toll-like receptor-9(TLR9) can recognize the foreign unmethylated CpG DNA, and thus intrigue a strong Th1 response which plays a crucial role in the innate and adaptive immune responses. To date, CpG oligodeoxynucleotide (ODN)-based TLR9 agonists have undergone four generations. Each generations' breakthroughs in immune activation, safety profiles and pharmacokinetic properties were confirmed by both preclinical and clinical studies. Areas covered: We reviewed the development and major clinical trials of TLR9 agonists and summarized the optimization strategies of each generation. The applications, limitations and prospects of TLR9 agonists in cancer immunotherapy are also discussed. Expert opinion: Clinical trials of CpG ODN TLR9 agonists as a single agent demonstrated insufficient efficacy to reverse the immunosuppressive status of majority of patients with high tumor burden. Therefore, more efforts are now been carried out in combination with chemotherapy, radiotherapy and immunotherapy maintenance therapy as well as vaccine adjuvant. Importantly, the synergistic and complementary effect of TLR9 agonists and tumor immune checkpoint inhibitor therapy is expected to exert greater potential. On the other hand, the double-edged sword effect of TLR9 activation in tumor and toxic effect reported in combination therapies should be noted and further studies required.
MeSH term(s)	Clinical Trials as Topic ; Humans ; Neoplasms/drug therapy ; Oligodeoxyribonucleotides/pharmacology ; Toll-Like Receptor 9/antagonists & inhibitors ; Toll-Like Receptor 9/drug effects
Chemical Substances	Oligodeoxyribonucleotides ; TLR9 protein, human ; Toll-Like Receptor 9
Language	English
Publishing date	2021-04-15
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2112544-2
ISSN	1744-8328 ; 1473-7140
ISSN (online)	1744-8328
ISSN	1473-7140
DOI	10.1080/14737140.2021.1915136
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5907: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells.

Kell, Sariah A / Kachura, Melissa A / Renn, Alex / Traquina, Paula / Coffman, Robert L / Campbell, John D

International immunopharmacology

2018 Volume 66, Page(s) 296–308

Abstract: ... clinical development of inhaled aerosolized DV281 as a combination therapy with anti-PD‑1 antibody ... the development of DV281, a C-class CpG-ODN, as an inhaled aerosolized immunotherapeutic for lung cancer to be ... PBMCs), stimulated interleukin‑6 production and proliferation in human B cells, and induced TLR9 ...

Abstract	CpG-motif-containing oligodeoxynucleotides (CpG-ODN) activate innate immunity through Toll-Like Receptor (TLR) 9 signaling and generate local immune responses when delivered directly to the lung. Herein we describe pharmacological studies in mice, cynomolgus monkeys, and in human primary cells which support the development of DV281, a C-class CpG-ODN, as an inhaled aerosolized immunotherapeutic for lung cancer to be combined with an inhibitor of the anti-programmed cell death protein 1 (PD‑1) immune checkpoint. In vitro, DV281 potently induced Interferon (IFN)‑α from monkey and human peripheral blood mononuclear cells (PBMCs), stimulated interleukin‑6 production and proliferation in human B cells, and induced TLR9-dependent cytokine responses from mouse splenocytes. Intranasal delivery of DV281 to mice led to substantial but transient cytokine and chemokine responses in the lung. Lung responses to repeated intranasal DV281 were partially to fully reversible 2 weeks after the final dose and were absent in TLR9-deficient mice. Single escalating doses of aerosolized DV281 in monkeys induced dose-dependent induction of IFN-regulated genes in bronchoalveolar lavage cells and blood. In a repeat-dose safety study in monkeys, inhaled DV281 was well-tolerated, and findings were mechanism of action-related and non-adverse. Co-culture of human PBMC with DV281 and anti-PD‑1 antibody did not augment cytokine or cellular proliferation responses compared to DV281 alone, indicating that the combination did not lead to dysregulated cytokine responses. These studies support clinical development of inhaled aerosolized DV281 as a combination therapy with anti-PD‑1 antibody for lung cancer immunotherapy.
MeSH term(s)	Administration, Inhalation ; Aerosols ; Animals ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; B-Lymphocytes/drug effects ; B-Lymphocytes/immunology ; Cell Proliferation ; Cells, Cultured ; Female ; Humans ; Immunotherapy/methods ; Interferon-alpha/metabolism ; Interleukin-6/metabolism ; Lung Neoplasms/immunology ; Lung Neoplasms/therapy ; Macaca fascicularis ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Oligodeoxyribonucleotides/pharmacology ; Programmed Cell Death 1 Receptor/immunology ; Toll-Like Receptor 9/agonists ; Toll-Like Receptor 9/genetics
Chemical Substances	Aerosols ; Antibodies, Monoclonal ; CPG-oligonucleotide ; Interferon-alpha ; Interleukin-6 ; Oligodeoxyribonucleotides ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor ; Toll-Like Receptor 9
Language	English
Publishing date	2018-11-29
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2043785-7
ISSN	1878-1705 ; 1567-5769
ISSN (online)	1878-1705
ISSN	1567-5769
DOI	10.1016/j.intimp.2018.11.019
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5408: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: TLR9 Monotherapy in Immune-Competent Mice Suppresses Orthotopic Prostate Tumor Development.

Miles, Mark A / Luong, Raymond / To, Eunice E / Erlich, Jonathan R / Liong, Stella / Liong, Felicia / Logan, Jessica M / O'Leary, John / Brooks, Doug A / Selemidis, Stavros

Cells

2024 Volume 13, Issue 1

Abstract: ... a direct role in prostate cancer pathogenesis, but TLR9 has been reported to contribute ... investigated the effect of TLR9 stimulation on prostate cancer progression in an immune-competent, syngeneic ... orthotopic mouse model of prostate cancer. Here, we utilized the class B synthetic agonist CPG-1668 ...

Abstract	Prostate cancer is ranked second in the world for cancer-related deaths in men, highlighting the lack of effective therapies for advanced-stage disease. Toll-like receptors (TLRs) and immunity have a direct role in prostate cancer pathogenesis, but TLR9 has been reported to contribute to both the progression and inhibition of prostate tumorigenesis. To further understand this apparent disparity, we have investigated the effect of TLR9 stimulation on prostate cancer progression in an immune-competent, syngeneic orthotopic mouse model of prostate cancer. Here, we utilized the class B synthetic agonist CPG-1668 to provoke a TLR9-mediated systemic immune response and demonstrate a significant impairment of prostate tumorigenesis. Untreated tumors contained a high abundance of immune-cell infiltrates. However, pharmacological activation of TLR9 resulted in smaller tumors containing significantly fewer M1 macrophages and T cells. TLR9 stimulation of tumor cells
MeSH term(s)	Humans ; Male ; Animals ; Mice ; Toll-Like Receptor 9 ; Prostatic Neoplasms/drug therapy ; Carcinogenesis ; Prostate ; Cell Transformation, Neoplastic
Chemical Substances	Toll-Like Receptor 9 ; TLR9 protein, human
Language	English
Publishing date	2024-01-02
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2661518-6
ISSN	2073-4409 ; 2073-4409
ISSN (online)	2073-4409
ISSN	2073-4409
DOI	10.3390/cells13010097
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Preclinical Development and Validation of Translational Temperature Sensitive Iodized Oil Emulsion Mediated Transcatheter Arterial Chemo-Immuno-Embolization for the Treatment of Hepatocellular Carcinoma.

Kim, Heegon / Choi, Bongseo / Mouli, Samdeep K / Choi, Hyunjun / Harris, Kathleen R / Kulik, Laura M / Lewandowski, Robert J / Kim, Dong-Hyun

Advanced healthcare materials

2023 Volume 12, Issue 26, Page(s) e2300906

Abstract: ... TLR9 agonist CpG oligodeoxynucleotide) is successfully performed using CpG-loaded Dox-PF127-LPD ... in vivo preclinical VX2 liver cancer rabbit model and N1S1 HCC rat model are demonstrated ... cancer immunity and tumor regression of TACIE, along with its favorable safety profile, indicate ...

Abstract	Herein a practical strategy for augmenting immune activation in transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) is presented. Pluronic F127 (PF127) is incorporated with Lipiodol (LPD) to achieve safe and effective delivery of therapeutic agents during transcatheter intra-arterial (IA) local delivery. Enhanced emulsion stability, IA infusion, embolic effect, safety, pharmacokinetics, and tumor response of Doxorubicin loaded PF127-LPD (Dox-PF127-LPD) for TACE in both in vitro and in vivo preclinical VX2 liver cancer rabbit model and N1S1 HCC rat model are demonstrated. Then, transcatheter arterial chemo-immuno-embolization (TACIE) combining TACE and local delivery of immune adjuvant (TLR9 agonist CpG oligodeoxynucleotide) is successfully performed using CpG-loaded Dox-PF127-LPD. Concurrent and safe local delivery of CpG and TACE during TACIE demonstrate leveraged TACE-induced immunogenic tumor microenvironment and augment systemic anti-tumor immunity in syngeneic N1S1 HCC rat model. Finally, the broad utility and enhanced therapeutic efficacy of TACIE are validated in the diethylnitrosamine-induced rat HCC model. TACIE using clinically established protocols and materials shall be a convenient and powerful therapeutic approach that can be translated to patients with HCC. The robust anti-cancer immunity and tumor regression of TACIE, along with its favorable safety profile, indicate its potential as a novel localized combination immunotherapy for HCC treatment.
MeSH term(s)	Humans ; Rats ; Animals ; Rabbits ; Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/pathology ; Liver Neoplasms/drug therapy ; Liver Neoplasms/pathology ; Emulsions ; Temperature ; Chemoembolization, Therapeutic/methods ; Ethiodized Oil/therapeutic use ; Doxorubicin/therapeutic use ; Treatment Outcome ; Tumor Microenvironment
Chemical Substances	Emulsions ; Ethiodized Oil (8008-53-5) ; Doxorubicin (80168379AG)
Language	English
Publishing date	2023-05-21
Publishing country	Germany
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2649576-4
ISSN	2192-2659 ; 2192-2640
ISSN (online)	2192-2659
ISSN	2192-2640
DOI	10.1002/adhm.202300906
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6966: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Inhibition of TLR7 and TLR9 Reduces Human Cholangiocarcinoma Cell Proliferation and Tumor Development.

Mohamed, Fatma El Zahraa / Jalan, Rajiv / Minogue, Shane / Andreola, Fausto / Habtesion, Abeba / Hall, Andrew / Winstanley, Alison / Damink, Steven Olde / Malagó, Massimo / Davies, Nathan / Luong, Tu Vinh / Dhillon, Amar / Mookerjee, Rajeshwar / Dhar, Dipok / Al-Jehani, Rajai Munir

Digestive diseases and sciences

2021 Volume 67, Issue 5, Page(s) 1806–1821

Abstract: ... cell line HuCCT1 was measured by MTS assay following treatment with CpG-ODN (TLR9 agonist), imiquimod (TLR7 ... agonist), chloroquine (TLR7 and TLR9 inhibitor) and IRS-954 (TLR7 and TLR9 antagonist). The in vivo ... were examined immunohistochemically for TLR4, TLR7, and TLR9 expression. Proliferation of human ICC ...

Abstract	Background: Toll-like receptors (TLRs) are key players in innate immunity and modulation of TLR signaling has been demonstrated to profoundly affect proliferation and growth in different types of cancer. However, the role of TLRs in human intrahepatic cholangiocarcinoma (ICC) pathogenesis remains largely unexplored. Aims: We set out to determine if TLRs play any role in ICCs which could potentially make them useful treatment targets. Methods: Tissue microarrays containing samples from 9 human ICCs and normal livers were examined immunohistochemically for TLR4, TLR7, and TLR9 expression. Proliferation of human ICC cell line HuCCT1 was measured by MTS assay following treatment with CpG-ODN (TLR9 agonist), imiquimod (TLR7 agonist), chloroquine (TLR7 and TLR9 inhibitor) and IRS-954 (TLR7 and TLR9 antagonist). The in vivo effects of CQ and IRS-954 on tumor development were also examined in a NOD-SCID mouse xenograft model of human ICC. Results: TLR4 was expressed in all normal human bile duct epithelium but absent in the majority (60%) of ICCs. TLR7 and TLR9 were expressed in 80% of human ICCs. However, TLR7 was absent in all cases of normal human bile duct epithelium and only one was TLR9 positive. HuCCT1 cell proliferation in vitro significantly increased following IMQ or CpG-ODN treatment (P < 0.03 and P < 0.002, respectively) but decreased with CQ (P < 0.02). In the mouse xenograft model there was significant reduction in size of tumors from CQ and IRS-954 treated mice compared to untreated controls. Conclusion: TLR7 and TLR9 should be further explored for their potential as actionable targets in the treatment of ICC.
MeSH term(s)	Animals ; Bile Duct Neoplasms/drug therapy ; Bile Ducts, Intrahepatic/metabolism ; Cell Proliferation ; Cholangiocarcinoma/drug therapy ; Humans ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Toll-Like Receptor 4 ; Toll-Like Receptor 7/agonists ; Toll-Like Receptor 7/metabolism ; Toll-Like Receptor 9/agonists ; Toll-Like Receptor 9/genetics ; Toll-Like Receptors/agonists
Chemical Substances	TLR7 protein, human ; TLR9 protein, human ; Tlr9 protein, mouse ; Toll-Like Receptor 4 ; Toll-Like Receptor 7 ; Toll-Like Receptor 9 ; Toll-Like Receptors
Language	English
Publishing date	2021-05-03
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	304250-9
ISSN	1573-2568 ; 0163-2116
ISSN (online)	1573-2568
ISSN	0163-2116
DOI	10.1007/s10620-021-06973-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui V Zs.35: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: [Development of Nucleic Acid-Based Adjuvant for Cancer Immunotherapy].

Kobiyama, Kouji / Ishii, Ken J

Gan to kagaku ryoho. Cancer & chemotherapy

2015 Volume 42, Issue 9, Page(s) 1040–1045

Abstract: ... vaccines and to act as mono-therapeutic anti-tumor agents. CpG ODN, an agonist for TLR9, is one ... rapidly progressed, with the research and development of cancer immunotherapy, including cancer ... Since the discovery of the human T cell-defined tumor antigen, the cancer immunotherapy field has ...

Abstract	Since the discovery of the human T cell-defined tumor antigen, the cancer immunotherapy field has rapidly progressed, with the research and development of cancer immunotherapy, including cancer vaccines, being conducted actively. However, the disadvantages of most cancer vaccines include relatively weak immunogenicity and immune escape or exhaustion. Adjuvants with innate immunostimulatory activities have been used to overcome these issues, and these agents have been shown to enhance the immunogenicity of cancer vaccines and to act as mono-therapeutic anti-tumor agents. CpG ODN, an agonist for TLR9, is one of the promising nucleic acid-based adjuvants, and it is a potent inducer of innate immune effector functions. CpG ODN suppresses tumor growth in the absence of tumor antigens and peptide administration. Therefore, CpG ODN is expected to be useful as a cancer vaccine adjuvant as well as a cancer immunotherapy agent. In this review, we discuss the potential therapeutic applications and mechanisms of CpG ODN for cancer immunotherapy.
MeSH term(s)	Adjuvants, Immunologic ; Animals ; Cancer Vaccines/administration & dosage ; Cancer Vaccines/immunology ; Humans ; Immunotherapy ; Neoplasms/immunology ; Neoplasms/therapy ; Nucleic Acids/administration & dosage ; Toll-Like Receptor 9/immunology
Chemical Substances	Adjuvants, Immunologic ; Cancer Vaccines ; Nucleic Acids ; Toll-Like Receptor 9
Language	Japanese
Publishing date	2015-09
Publishing country	Japan
Document type	English Abstract ; Journal Article
ZDB-ID	604842-0
ISSN	0385-0684
ISSN	0385-0684
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2573: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Recognition of nucleic acids by Toll-like receptors and development of immunomodulatory drugs.

Kuznik, A / Panter, G / Jerala, R

Current medicinal chemistry

2009 Volume 17, Issue 18, Page(s) 1899–1914

Abstract: ... endosomal TLR ligands. So far, inhibitory nucleic acids against TLR7, TLR8 and TLR9 as well as small ... Toll-like receptors TLR3, TLR7, TLR8 and TLR9. Recent discoveries significantly improved our understanding ... through two nucleic acid binding sites of TLR3 ectodomain, activation of TLR9 by phosphodiester backbone ...

Abstract	Microbial as well as endogenous nucleic acids are recognized by a group of endosomal Toll-like receptors TLR3, TLR7, TLR8 and TLR9. Recent discoveries significantly improved our understanding of molecular mechanism of their activation and their physiological role. Those include recognition of dsRNA through two nucleic acid binding sites of TLR3 ectodomain, activation of TLR9 by phosphodiester backbone of ssDNA, independent of the nucleotide sequence and phosphorothioate modified bonds, and the role of proteolysis in activation of TLR9. In addition, proteins that chaperone nucleic acids, such as HMGB1 or LL-37, have been described to mediate TLR activation. There is growing evidence that supports involvement of endosomal TLRs in a number of autoimmune diseases, suggesting a therapeutic potential of immunomodulatory endosomal TLR ligands. So far, inhibitory nucleic acids against TLR7, TLR8 and TLR9 as well as small compounds targeting downstream signal transduction of single or several endosomal TLRs have been reported. TLR-targeting drugs have been included in clinical trials as vaccine adjuvants or as therapeutic agents for the treatment of diseases, ranging from cancer, infections, asthma and allergy to autoimmune diseases.
MeSH term(s)	Animals ; Autoimmune Diseases/drug therapy ; Autoimmune Diseases/immunology ; Humans ; Immunologic Factors/immunology ; Immunologic Factors/pharmacology ; Nucleic Acids/immunology ; Signal Transduction ; Toll-Like Receptors/agonists ; Toll-Like Receptors/antagonists & inhibitors ; Toll-Like Receptors/immunology
Chemical Substances	Immunologic Factors ; Nucleic Acids ; Toll-Like Receptors
Language	English
Publishing date	2009-10-26
Publishing country	United Arab Emirates
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1319315-6
ISSN	1875-533X ; 0929-8673
ISSN (online)	1875-533X
ISSN	0929-8673
DOI	10.2174/092986710791163957
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4432: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9.

Vollmer, Jörg

Expert opinion on biological therapy

2002 Volume 5, Issue 5, Page(s) 673–682

Abstract: ... asthma and allergy. TLR9 agonists represent a new class of small (8-30 bases long), easily synthesised ... as vaccine adjuvants, stand-alone therapy or in combination with other therapies in cancer, infectious diseases or ... agonists as highly effective targeted immunomodulatory drugs with broad potential applications ...

Abstract	Oligodeoxynucleotides (ODNs) with unmethylated deoxycytosine-deoxyguanosine (CpG) motifs are recognised by Toll-like receptor (TLR)9 expressed in specialised cell subsets of the human immune system, B cells and plasmacytoid dendritic cells. TLR9-mediated stimulation of the immune system leads to a plethora of directed effects linking innate to adaptive immune responses. This allows the use of TLR9 agonists as highly effective targeted immunomodulatory drugs with broad potential applications as vaccine adjuvants, stand-alone therapy or in combination with other therapies in cancer, infectious diseases or asthma and allergy. TLR9 agonists represent a new class of small (8-30 bases long), easily synthesised, non-antisense ODN pharmaceuticals.
MeSH term(s)	Adjuvants, Immunologic/therapeutic use ; Clinical Trials as Topic/statistics & numerical data ; CpG Islands/immunology ; Humans ; Ligands ; Oligodeoxyribonucleotides/immunology ; Technology, Pharmaceutical/methods ; Technology, Pharmaceutical/trends ; Toll-Like Receptor 9/immunology
Chemical Substances	Adjuvants, Immunologic ; Ligands ; Oligodeoxyribonucleotides ; Toll-Like Receptor 9
Language	English
Publishing date	2002-06-15
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2052501-1
ISSN	1744-7682 ; 1471-2598
ISSN (online)	1744-7682
ISSN	1471-2598
DOI	10.1517/14712598.5.5.673
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6094: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.

Schetter, Christian / Vollmer, Jörg

Current opinion in drug discovery & development

2004 Volume 7, Issue 2, Page(s) 204–210

Abstract: ... immune system, allows the use of TLR9 agonists as highly effective vaccine adjuvants for infectious diseases ... and as stand-alone therapies or in combination with other therapies in cancer. ... of immune responses. The pathogen structures that are recognized by TLR9 in bacterial or viral DNA are deoxycytidyl ...

Abstract	Upon microbial infection, a host has to mount a multiplicity of immune responses that target the invading pathogen. This is achieved in part by the use of particular receptors expressed on mammalian innate immune cells, the toll-like receptors (TLRs). Recognition of a given microbial molecular structure, such as bacterial or viral DNA, leads to the activation of signaling pathways that result in distinct sets of immune responses. The pathogen structures that are recognized by TLR9 in bacterial or viral DNA are deoxycytidyl-deoxyguanosine dinucleotides (CpGs) in specific sequence contexts (CpG motifs). The stimulatory activity of pathogen DNA can be mimicked by synthetic oligodeoxynucleotides (ODNs) containing such motifs (CpG ODNs). The TLR9-mediated stimulation of the vertebrate innate immune system, and subsequently of the adaptive immune system, allows the use of TLR9 agonists as highly effective vaccine adjuvants for infectious diseases, and as stand-alone therapies or in combination with other therapies in cancer.
MeSH term(s)	Adjuvants, Immunologic/pharmacology ; Adjuvants, Immunologic/therapeutic use ; Animals ; CpG Islands/immunology ; DNA-Binding Proteins/agonists ; Drug Design ; Humans ; Immunity, Innate/drug effects ; Immunity, Innate/immunology ; Infection/drug therapy ; Infection/immunology ; Infection/microbiology ; Oligodeoxyribonucleotides/pharmacology ; Oligodeoxyribonucleotides/therapeutic use ; Receptors, Cell Surface/agonists ; Toll-Like Receptor 9 ; Vaccines, Synthetic/immunology ; Vaccines, Synthetic/pharmacology ; Vaccines, Synthetic/therapeutic use
Chemical Substances	Adjuvants, Immunologic ; CPG-oligonucleotide ; DNA-Binding Proteins ; Oligodeoxyribonucleotides ; Receptors, Cell Surface ; TLR9 protein, human ; Toll-Like Receptor 9 ; Vaccines, Synthetic
Language	English
Publishing date	2004-03
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1461136-3
ISSN	2040-3437 ; 1367-6733
ISSN (online)	2040-3437
ISSN	1367-6733
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5276: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito